[go: up one dir, main page]

WO2007021970A3 - Stable pharmaceutical formulations and methods of use thereof - Google Patents

Stable pharmaceutical formulations and methods of use thereof Download PDF

Info

Publication number
WO2007021970A3
WO2007021970A3 PCT/US2006/031439 US2006031439W WO2007021970A3 WO 2007021970 A3 WO2007021970 A3 WO 2007021970A3 US 2006031439 W US2006031439 W US 2006031439W WO 2007021970 A3 WO2007021970 A3 WO 2007021970A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
pharmaceutical formulations
pharmaceutically active
stable pharmaceutical
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/031439
Other languages
French (fr)
Other versions
WO2007021970A2 (en
Inventor
Heow Meng Tan
Ming Ye
Thomas F Mcgrath
Kevin A Johnston
Maria Micalizzi
Patrick Mckenna
Martin Patrick Redmon
Murali K Vuppala
Gary F Musso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Praecis Pharmaceuticals Inc
Original Assignee
Praecis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praecis Pharmaceuticals Inc filed Critical Praecis Pharmaceuticals Inc
Publication of WO2007021970A2 publication Critical patent/WO2007021970A2/en
Anticipated expiration legal-status Critical
Publication of WO2007021970A3 publication Critical patent/WO2007021970A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides pharmaceutical formulations characterized by improved stability of the pharmaceutically active compounds contained therein, methods for preparing the same, and methods of use thereof. The pharmaceutical compositions of the present invention comprise a stable water-insoluble complex of a pharmaceutically active compound and a carrier macromolecule. The advantages of the pharmaceutical compositions of the invention include, for example, the increased stability of a pharmaceutically active compound contained therein.
PCT/US2006/031439 2005-08-15 2006-08-14 Stable pharmaceutical formulations and methods of use thereof Ceased WO2007021970A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US70853605P 2005-08-15 2005-08-15
US60/708,536 2005-08-15
US73254505P 2005-11-02 2005-11-02
US60/732,545 2005-11-02
US79855506P 2006-05-08 2006-05-08
US60/798,555 2006-05-08

Publications (2)

Publication Number Publication Date
WO2007021970A2 WO2007021970A2 (en) 2007-02-22
WO2007021970A3 true WO2007021970A3 (en) 2008-10-09

Family

ID=37667924

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/031439 Ceased WO2007021970A2 (en) 2005-08-15 2006-08-14 Stable pharmaceutical formulations and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2007021970A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2060253A1 (en) 2007-11-14 2009-05-20 Laboratorios Farmaceuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
DE102007003765A1 (en) * 2007-01-19 2008-07-24 Farco-Pharma Gmbh Pharmaceutical composition for the treatment of incontinence
EP2170362B1 (en) * 2007-06-26 2015-11-04 Merck Sharp & Dohme Corp. Lyophilized anti-fungal composition
CN102697733B (en) * 2007-12-04 2015-08-12 上海抗体药物国家工程研究中心有限公司 A kind of interior parcel immunotoxin connects the Poly(D,L-lactide-co-glycolide nano-particle of antibody outward
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
CN101810583B (en) * 2010-04-09 2013-09-11 佟丽 HIV (Human Immunodeficiency Virus) fusion inhibitor slow-release microsphere
CN102580056B (en) * 2011-12-16 2014-04-09 深圳市健元医药科技有限公司 Controlled-release injection containing antidiuresis components and preparation method thereof
JP6539274B2 (en) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド Extruded immediate release abuse deterrent pills
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2016010771A1 (en) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
JP2017531026A (en) 2014-10-20 2017-10-19 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド Sustained release abuse deterrent liquid filler form
KR101945498B1 (en) * 2015-11-04 2019-02-08 포항공과대학교 산학협력단 Composition for skin permeation comprising cationic molecular transporters and protein
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
DK3506921T3 (en) 2016-08-31 2023-07-31 Mapi Pharma Ltd DEPOT SYSTEMS INCLUDING GLATIRAMER ACETATE
CN106729717A (en) * 2016-12-12 2017-05-31 深圳市健翔生物制药有限公司 The analogs of GLP 1 and ziconotide composition sustained-release microsphere preparation
JP7602322B2 (en) 2017-03-26 2024-12-18 マピ ファーマ リミテッド Glatiramer depot system for treating progressive multiple sclerosis
MX2020005438A (en) 2017-12-20 2020-12-03 Purdue Pharma Lp Abuse deterrent morphine sulfate dosage forms.
US20210000910A1 (en) 2019-07-03 2021-01-07 Jysk Skin Solutions Pte Ltd Topical compositions
US12083204B2 (en) 2022-06-02 2024-09-10 L'oreal Topical composition for homeostatic delivery of nitric oxide and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025642A2 (en) * 1996-12-11 1998-06-18 Praecis Pharmaceuticals Incorporated Pharmaceutical formulations comprising a water-insoluble complex for sustained drug delivery
WO1999055358A1 (en) * 1998-04-27 1999-11-04 Praecis Pharmaceuticals Incorporated Methods for treating hot flashes and gynaecomastia
WO2002022154A2 (en) * 2000-09-13 2002-03-21 Praecis Pharmaceuticals Incorporated Pharmaceutical compositions for sustained drug delivery
WO2004056388A1 (en) * 2002-12-19 2004-07-08 Praecis Pharmaceuticals, Inc. Methods of enhancing immune system function in a subject
WO2007022254A2 (en) * 2005-08-15 2007-02-22 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025642A2 (en) * 1996-12-11 1998-06-18 Praecis Pharmaceuticals Incorporated Pharmaceutical formulations comprising a water-insoluble complex for sustained drug delivery
US6180608B1 (en) * 1996-12-11 2001-01-30 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US20030171296A1 (en) * 1996-12-11 2003-09-11 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
EP1398037A2 (en) * 1996-12-11 2004-03-17 Praecis Pharmaceuticals Incorporated Pharmaceutical formulations comprising a water-insoluble complex for sustained drug delivery
WO1999055358A1 (en) * 1998-04-27 1999-11-04 Praecis Pharmaceuticals Incorporated Methods for treating hot flashes and gynaecomastia
WO2002022154A2 (en) * 2000-09-13 2002-03-21 Praecis Pharmaceuticals Incorporated Pharmaceutical compositions for sustained drug delivery
WO2004056388A1 (en) * 2002-12-19 2004-07-08 Praecis Pharmaceuticals, Inc. Methods of enhancing immune system function in a subject
WO2007022254A2 (en) * 2005-08-15 2007-02-22 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery

Also Published As

Publication number Publication date
WO2007021970A2 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
WO2007021970A3 (en) Stable pharmaceutical formulations and methods of use thereof
WO2002074247A3 (en) Pharmaceutical formulations for sustained release
WO2004074244A3 (en) Pyrimidine compounds
WO2007146248A3 (en) Stable laquinimod preparations
WO2007067506A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
WO2007022255A3 (en) Pharmaceutical formulations for sustained release
WO2006068826A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
WO2007027941A3 (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
WO2007008752A3 (en) Sustained release pharmaceutical compositions for highly water soluble drugs
WO2003095455A3 (en) Substituted pyrazolopyrimidines
WO2003037860A3 (en) Purine analogs having hsp90-inhibiting activity
WO2002048147A3 (en) Pyrazolopyridines
WO2004093800A3 (en) Thyronamine derivatives and analogs and methods of use thereof
WO2001095856A3 (en) Urea derivative useful as an anti-cancer agent and process for preparing same
WO2002048148A3 (en) Pyrazolopyridine derivatives
BRPI0508579A (en) compound, pharmaceutical composition, and use of a compound
WO2005112633A3 (en) Compounds and compositions for delivering active agents
WO2009105969A8 (en) Epothilone analogues, their pharmaceutical compositions, their use and their preparations
WO2009060952A1 (en) Novel preparation
WO2007075972A3 (en) Chlorite formulations, and methods of preparation and use thereof
WO2007044796A3 (en) Pyridazinone compounds as calcilytics
WO2006096444A3 (en) Chemical compounds
TW200716618A (en) Chemical compounds
WO2004098594A3 (en) Dosage form containing pantoprazole as active ingredient
WO2005054172A3 (en) Jasmonate derivative compounds, pharmaceuticals compositions and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIUGHTS PURSUANT TO RULE 112(1) EPC

122 Ep: pct application non-entry in european phase

Ref document number: 06801293

Country of ref document: EP

Kind code of ref document: A2